Effects of amrinone on myocardial energetics in severe congestive heart failure.

Abstract

Animal and human studies suggest that amrinone can cause significant improvement in the systemic hemodynamics of patients with severe congestive heart failure (CHF), and do so without increasing myocardial oxygen consumption. Because patients with CHF appear to be vulnerable to any further worsening of the myocardial oxygen supply-and-demand balance, amrinone may have a distinct advantage over catecholamine agents that tend to increase myocardial oxygen demand.

• Authors: D S Baim
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 56 Issue 3 Pg. 16B-18B (Jul 22 1985) ISSN: 0002-9149 [Print] United States
• PMID: 3161318 (Publication Type: Journal Article)

Chemical References

• Aminopyridines
• Cardiotonic Agents
• Imidazoles
• Phosphodiesterase Inhibitors
• Pyridones
• Enoximone
• Milrinone
• Amrinone
• Isoproterenol

Topics

• Aminopyridines (pharmacology, therapeutic use)
• Amrinone
• Animals
• Cardiotonic Agents (pharmacology, therapeutic use)
• Coronary Circulation (drug effects)
• Dogs
• Enoximone
• Heart (drug effects)
• Heart Failure (drug therapy, metabolism)
• Humans
• Imidazoles (pharmacology)
• Isoproterenol (pharmacology)
• Milrinone
• Myocardial Contraction (drug effects)
• Myocardium (metabolism)
• Oxygen Consumption (drug effects)
• Phosphodiesterase Inhibitors (pharmacology)
• Pyridones (pharmacology)